Dysregulated alveolar epithelial cell progenitor function and identity in Hermansky-Pudlak syndrome pulmonary fibrosis

Joanna Y. Wang,Nigel S. Michki,Sneha Sitaraman,Brandon J. Banaschewski,Susan M. Lin,Jeremy B. Katzen,Maria C. Basil,Edward Cantu,Jarod A. Zepp,David B. Frank,Lisa R. Young

DOI: https://doi.org/10.1101/2023.06.17.545390

2024-06-01

Abstract:Hermansky-Pudlak syndrome (HPS) is a genetic disorder of endosomal protein trafficking associated with pulmonary fibrosis in specific subtypes, including HPS-1 and HPS-2. Single mutant HPS1 and HPS2 mice display increased fibrotic sensitivity while double mutant HPS1/2 mice exhibit spontaneous fibrosis with aging, which has been attributed to HPS mutations in alveolar epithelial type II (AT2) cells. We utilized HPS mouse models and human lung tissue to investigate mechanisms of AT2 cell dysfunction driving fibrotic remodeling in HPS. Starting at 8 weeks of age, HPS mice exhibited progressive loss of AT2 cell numbers. HPS AT2 cell was impaired ex vivo and in vivo. Incorporating AT2 cell lineage tracing in HPS mice, we observed aberrant differentiation with increased AT2-derived alveolar epithelial type I cells. Transcriptomic analysis of HPS AT2 cells revealed elevated expression of genes associated with aberrant differentiation and p53 activation. Lineage tracing and modeling studies demonstrated that HPS AT2 cells were primed to persist in a Krt8+ reprogrammed transitional state, mediated by p53 activity. Intrinsic AT2 progenitor cell dysfunction and p53 pathway dysregulation are novel mechanisms of disease in HPS-related pulmonary fibrosis, with the potential for early targeted intervention before the onset of fibrotic lung disease.

Cell Biology

What problem does this paper attempt to address?

This paper mainly explores the mechanisms of pulmonary fibrosis associated with Hermansky-Pudlak syndrome (HPS), a genetic disorder related to defects in endosomal protein trafficking. The study found that in certain subtypes of HPS, such as HPS-1 and HPS-2, pulmonary fibrosis develops. Using HPS mouse models and human lung tissue, researchers observed a gradual decrease in the number of alveolar epithelial type 2 (AT2) cells in the lungs of HPS mice at an early stage of the disease, around 8 weeks of age.

The paper indicates that HPS AT2 cells exhibit impaired function both in vitro and in vivo, characterized by abnormal differentiation and increased conversion to alveolar epithelial type 1 (AT1) cells. Transcriptomic analysis revealed upregulation of gene expression associated with abnormal differentiation and p53 activation. Lineage tracing revealed that HPS AT2 cells were induced to enter a p53-mediated Krt8+ reprogramming transitional state, which persists in HPS1/2 mice and is consistent with lung tissue from human HPS-1 patients.

The study also suggests that intrinsic progenitor cell dysfunction of AT2 cells and p53 pathway dysregulation are novel mechanisms of HPS-related pulmonary fibrosis, providing potential avenues for early intervention and implying common disease mechanisms between HPS pulmonary fibrosis and other genetic and idiopathic fibrotic lung diseases.

In summary, this paper aims to reveal the key cellular and molecular mechanisms underlying HPS pulmonary fibrosis, particularly the dysfunction of AT2 cells and how it leads to lung tissue remodeling and fibrosis. These findings may contribute to the development of early treatment strategies targeting HPS pulmonary fibrosis.